289 related articles for article (PubMed ID: 17659486)
21. Structural plasticity in G-protein coupled receptors as demonstrated by the allosteric actions of homocysteine and computer-assisted analysis of disordered domains.
Agnati LF; Leo G; Genedani S; Andreoli N; Marcellino D; Woods A; Piron L; Guidolin D; Fuxe K
Brain Res Rev; 2008 Aug; 58(2):459-74. PubMed ID: 18022243
[TBL] [Abstract][Full Text] [Related]
22. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors.
Kenakin T
Trends Pharmacol Sci; 2007 Aug; 28(8):407-15. PubMed ID: 17629960
[TBL] [Abstract][Full Text] [Related]
23. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.
Keov P; Sexton PM; Christopoulos A
Neuropharmacology; 2011 Jan; 60(1):24-35. PubMed ID: 20637785
[TBL] [Abstract][Full Text] [Related]
24. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
Bhattacharya S; Hall SE; Vaidehi N
J Mol Biol; 2008 Oct; 382(2):539-55. PubMed ID: 18638482
[TBL] [Abstract][Full Text] [Related]
25. Activation of G protein-coupled receptors.
Deupi X; Kobilka B
Adv Protein Chem; 2007; 74():137-66. PubMed ID: 17854657
[TBL] [Abstract][Full Text] [Related]
26. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
27. New insights into GPCR function: implications for HTS.
Eglen RM; Reisine T
Methods Mol Biol; 2009; 552():1-13. PubMed ID: 19513638
[TBL] [Abstract][Full Text] [Related]
28. Emerging opportunities for allosteric modulation of G-protein coupled receptors.
Wang CI; Lewis RJ
Biochem Pharmacol; 2013 Jan; 85(2):153-62. PubMed ID: 22975406
[TBL] [Abstract][Full Text] [Related]
29. Inverse agonists: tools to reveal ligand-specific conformations of G protein-coupled receptors.
Prather PL
Sci STKE; 2004 Jan; 2004(215):pe1. PubMed ID: 14722344
[TBL] [Abstract][Full Text] [Related]
30. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology.
DeWire SM; Violin JD
Circ Res; 2011 Jul; 109(2):205-16. PubMed ID: 21737816
[TBL] [Abstract][Full Text] [Related]
31. Dimerization and oligomerization of G-protein-coupled receptors: debated structures with established and emerging functions.
Szidonya L; Cserzo M; Hunyady L
J Endocrinol; 2008 Mar; 196(3):435-53. PubMed ID: 18310440
[TBL] [Abstract][Full Text] [Related]
32. When simple agonism is not enough: emerging modalities of GPCR ligands.
Smith NJ; Bennett KA; Milligan G
Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
[TBL] [Abstract][Full Text] [Related]
33. Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening.
Eglen RM; Bosse R; Reisine T
Assay Drug Dev Technol; 2007 Jun; 5(3):425-51. PubMed ID: 17638542
[TBL] [Abstract][Full Text] [Related]
34. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
[TBL] [Abstract][Full Text] [Related]
35. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.
Mohr K; Schmitz J; Schrage R; Tränkle C; Holzgrabe U
Angew Chem Int Ed Engl; 2013 Jan; 52(2):508-16. PubMed ID: 23225228
[TBL] [Abstract][Full Text] [Related]
36. Signaling mechanisms of GPCR ligands.
Strange PG
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):196-202. PubMed ID: 18283607
[TBL] [Abstract][Full Text] [Related]
37. Allosteric modulation of G protein-coupled receptors.
Soudijn W; van Wijngaarden I; IJzerman AP
Curr Opin Drug Discov Devel; 2002 Sep; 5(5):749-55. PubMed ID: 12630295
[TBL] [Abstract][Full Text] [Related]
38. Efficacy as a vector: the relative prevalence and paucity of inverse agonism.
Kenakin T
Mol Pharmacol; 2004 Jan; 65(1):2-11. PubMed ID: 14722230
[TBL] [Abstract][Full Text] [Related]
39. Ligand binding and micro-switches in 7TM receptor structures.
Nygaard R; Frimurer TM; Holst B; Rosenkilde MM; Schwartz TW
Trends Pharmacol Sci; 2009 May; 30(5):249-59. PubMed ID: 19375807
[TBL] [Abstract][Full Text] [Related]
40. Receptor-mediated activation of heterotrimeric G-proteins: current structural insights.
Johnston CA; Siderovski DP
Mol Pharmacol; 2007 Aug; 72(2):219-30. PubMed ID: 17430994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
